Enovis Reports 3% Q4 Sales Rise to $576M, Takes $501M Impairment
Enovis’ Q4 net sales reached $576 million, up 3%, while a $501 million goodwill impairment drove a $519 million net loss and adjusted EBITDA totaled $112 million. Full-year 2025 sales grew 7% to $2.2 billion (6% organic) with Reconstructive up 10% and adjusted EBITDA of $403 million.
1. Fourth Quarter Financial Results
In Q4, Enovis achieved net sales of $576 million, a 3% increase on a reported basis driven by 7% reported growth in Global Reconstructive and flat performance in Prevention & Recovery. The period included a $501 million goodwill impairment, resulting in a $519 million net loss from continuing operations, while adjusted EBITDA was $112 million.
2. Full Year 2025 Results
For the full year 2025, net sales reached $2.2 billion, up 7% reported and 6% organically, with Reconstructive sales rising 10% and Prevention & Recovery sales climbing 4%. The company recorded a $1,182 million net loss that included a $1,050 million goodwill impairment and reported adjusted EBITDA of $403 million.
3. 2026 Financial Outlook
Enovis expects 2026 revenue of $2.31–2.37 billion, reflecting 4–6% organic growth, with adjusted EBITDA projected at $425–435 million and adjusted earnings per share of $3.52–3.73.